significantly ameliorated disease activity compared to anti-TL1A antibody and placebo. In addition, omilancor outperformed anti-TL1A antibodies against histological measures and in downregulating inflammatory genes implicated in the recruitment and...
Vision and Ophthalmology (ARVO) conference, from May 4 – 8, including the introduction of the new ZEISS Research Data Platform (ZEISS RDP), and a spotlight on the ongoing research collaboration with Boehringer Ingelheim to accelerate personalized,...
Co., Ltd., a pioneering South Korean company in drug development and commercialization. SK Life Science Labs (formerly Proteovant Therapeutics) exploits the ubiquitin-protease system (UPS) to discover and develop transformative medicines for the...
general, past studies have been limited by reporting gross changes in body composition using DEXA, which did not provide information on either muscle mass or myosteatosis. As anti-obesity medications are achieving greater weight reductions, it is...
Capture Therapy (BNCT). The company’s mission is to create a highly targeted, minimally invasive cancer therapy platform capable of treating the most resistant tumors with unprecedented precision. About The Ohio State University Comprehensive...
United States, Althea’s assets combine with PCI’s existing sterile fill-finish and advanced drug delivery operations to form a world-class, large-scale manufacturing hub in San Diego, complete with state-of-the-art large-scale aseptic facilities...
wearable therapeutics. The Jewel Patch-WCD received the European Union’s CE mark certification and Great Britain’s UK Conformity Assessed (UKCA) marking in January 2024. Dr. Uday N. Kumar, Founder, President, and CEO of Element Science, reflected...
the trial on the 15th April 2025 and is expected to be completed in Q3 2025. Stablepharma’s next-generation technology platform StablevaX™ reformulates existing and new vaccines and biologicals into thermostable products that do not require cold...
the target inhibition potency of commercial monospecific antibodies, but in a simple bispecific immunoglobulin G (IgG) format. Currently, these candidates are in final lead selection studies and manufacturing, in parallel, to prepare for the...
and extreme cold sensitivity, affecting the hands, feet, and oral cavity — compromising a patient's ability to perform routine daily activities. For many patients, peripheral neuropathy becomes the primary reason for dose reductions, treatment...
(LPS), peptidoglycan (PGN), and lipoteichoic acid (LTA) —three key bacterial cell wall components. The vaccine is also formulated with a universal T cell epitope and adjuvanted with AddaVax to boost immunogenicity. “LHNVD-303 is a broad-based...
(WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations: The Rare Pediatric Disease Designation (RPDD) incentivizes therapies...
commitment to broadening the applications of HEPZATO and the underlying hepatic delivery system, positioning us as a platform technology that can offer directed treatment options for a variety of liver-dominant cancers.” About Delcath Systems,...
Branded Specialty at Endo. "With a mix of tactical practice, videos of real procedures, and the inclusion of practical information, the simulator is an example of innovation that can enhance patient care." The Spatial Computing Injection Simulator...
a range of disease areas including hematology, oncology, immunology, and rare diseases as well as novel technology platforms. Mr. Messerlian joined Creyon's Board of Directors as Executive Chairman and Acting CEO in early fall 2024. He brings...
Novocure announced that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) concurrently with immune checkpoint inhibitors or docetaxel who have...
support patient treatment selection, we're advancing care across the oncology spectrum, solidifying our commitment to transforming cancer diagnostics and improving patient outcomes." Labcorp Plasma Detect: Advanced Risk Assessment for Colon Cancer...
capabilities. "By integrating true single cell level multi-omics data with ctDNA, OncoIncytes provides unparalleled information to oncologists that enhances critical clinical decisions," said Mohan Uttarwar, CEO and co-founder of 1Cell.Ai. "This...
drug development. “Our collaboration partner, Renova Health has used its AI and machine learning technology platform to analyze and identify optimal patient pools and study sites, enabling a swift and efficient progression of our study series over...
based on dermatologist-tested principles, integrating medical-grade phototherapy technology into a small, portable format. The goal? To make advanced fungal treatment accessible, affordable, and incredibly easy to use. Its intuitive, ergonomic...
